Overview

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor

Status:
Recruiting

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of injectable PEG-Irinotecan in patients with malignant solid tumors

Phase:

Phase 1

Details

Lead Sponsor:

JenKem Technology Co., Ltd.